BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
about
Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancerTargeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.Targeted drug discovery for pediatric leukemia.The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemiaFLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
P2860
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
@ast
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
@en
type
label
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
@ast
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
@en
prefLabel
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
@ast
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
@en
P2093
P2860
P356
P1476
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2011.564
P407
P577
2011-12-20T00:00:00Z